For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

This Collection provides updated research from the Immune cell engineering for cancer therapy 2024 Collection. Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...